Market News

Gilead (NASDAQ: GILD) Ups the Ante Against Counterfeit HIV Drug Ring

Gilead Sciences (NASDAQ: GILD) scored a win against alleged counterfeiters as a federal judge in New York ordered the freezing of assets of different people and entities accused of distributing counterfeit bottles of the biopharmaceutical company’s HIV drugs, Reuters reported on Thursday.

The report stated that according to court filings, Gilead has been pursuing these counterfeiters and has unearthed a massive nationwide operation “staggering in scope” which is responsible for selling millions of dollars worth of counterfeit bottles of its top sellers Descovy, Genvoya, and Biktarvy.

Reuters stated that HIV drugs made up around 60% of Gilead’s $12.6 billion revenue in the year’s first half.

Is GILD a Buy?

Analysts are cautiously optimistic about GILD with a Moderate Buy consensus rating based on five Buys and 10 Holds.

GILD stock has an average price forecast of $72.43 implying an upside potential of 13.3% at current levels.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More